Navigation Links
Psychiatric Medication Spending Growth Slows, According to New Thomson Reuters Research
Date:2/1/2012

WASHINGTON, Feb. 1, 2012 /PRNewswire/ -- The national growth rate for psychiatric medication spending has declined significantly, according to a new study conducted by researchers from Thomson Reuters (Healthcare) and the Substance Abuse and Mental Health Services Administration (SAMHSA).

(Logo: http://photos.prnewswire.com/prnh/20090507/NY12658LOGO )

The paper, which appears in the January 2012 issue of Psychiatric Services, underlines falling prices of psychiatric medications as one of the key contributors that has enabled the annual growth rate of psychiatric drug expenditures per patient to dip from 18.5 percent from 1997–2001 to 6.3 percent from 2001–2008. The decline in average prices was driven, in turn, by the entry of generic products—particularly generic antidepressants. Generics grew from 36% of psychiatric prescriptions filled in 1997 to 70% in 2008.

The number of new users of psychiatric medications also slowed during the 11–year study period. The growth in users of psychiatric drugs declined from 7% (1997–2001) to 2% (2001–2008).

"Employers and insurers have been concerned with the rate of increase in psychiatric drug costs.  As a result, they have implemented measures to control the cost of psychiatric medication prescriptions, such as step therapy, tiered payment, and other proactive cost-control measures," said Tami Mark, Ph.D., the paper's lead author and Senior Director, Thomson Reuters. "The high growth in spending during the late 1990s and into the early years of the next decade appears to have been a temporary phenomenon fueled by the introduction of new medications still on patent as well as by the rising use of those medications."

Data were compiled for the report from the Thomson Reuters MarketScan® Commercial Claims and Encounters Database, which provided private insurance claims records from approximately 30 million covered individuals. Information about prescription drug spending came from claims for prescription drugs that were filled through retail and mail-order pharmacies. Additional data came from SAMHSA spending estimates and the Medical Expenditure Panel Survey.

"Although the availability of lower-priced generic medication is good news, there may also be a damaging effect," Mark said. "Pharmaceutical companies appear to be slowing research and development on new psychiatric drugs. This may be related to the substantial penetration of generic alternatives and cost-containment policies surrounding branded products. It will be important to watch this trend closely to ensure that new psychiatric therapies are continuing to populate the drug development pipeline."

About the Substance Abuse and Mental Health Services Administration

SAMHSA is a public health agency within the Department of Health and Human Services that was established in 1992. The mission of the funding agency is to reduce the impact of mental and substance use disorders on America's communities. The agency provides leadership in the provision of behavioral health services to improve the quality and availability of prevention, treatment, and recovery support services. It also supports States, Territories, Tribes, communities, and local organizations through competitive grant and contract programs.  Information about the agency and its strategic initiatives is available at http://www.samhsa.gov/.

About Thomson Reuters

Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, healthcare and science and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 55,000 people and operates in over 100 countries. For more information, go to www.thomsonreuters.com.


'/>"/>
SOURCE Thomson Reuters
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
2. Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting
3. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
4. Data Presented at the American Psychiatric Association (APA) Annual Meeting Demonstrate Iloperidones Efficacy and Safety, With Low Rates of Movement and Metabolic Adverse Events
5. Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting
6. CNS Response, Inc. Provides Review of Poster Session Delivered at the American Psychiatric Association 161st Annual Meeting
7. Ridge Diagnostics, Inc. Clinical Data on Blood Test for Depression Presented at American Psychiatric Association Annual Meeting
8. Mayo Clinic Proceedings Reviews Deep Brain Stimulation to Treat Psychiatric Diseases
9. Shire to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30
10. Intra-Cellular Therapies Announces the Results of a Phase I PET Study for ITI-007 for the Treatment of Schizophrenia and Other Psychiatric Disorders
11. FDA Approves NDA That Includes Psychiatric Data Collected by Centralized Raters
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... 2017 Endo International plc (NASDAQ: ENDP ) ... of its senior management team will host a conference call and ... The dial-in number to access the call is ... the passcode is 6086379. Please dial in 10 minutes prior to ... replay of the call will be available from May 9, 2017 ...
(Date:4/20/2017)... , April 20, 2017  Cogentix Medical, Inc. ... on providing the Urology, Uro/Gyn and Gynecology markets ... Ash Keswani has joined the Company as Senior ... newly created position, Mr. Keswani will report directly ... "Our organization is delighted that Ash ...
(Date:4/20/2017)... 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), a ... significant unmet medical needs, today announced that it ... product development program, based on its proprietary self-delivering ... Dermatology (SID) 76 th Annual Meeting.  The ... sciences relevant to skin health and disease through ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... April 28, 2017 , ... Datta Endoscopic ... has joined the revolutionary endoscopic practice under Dr. Datta. Patel is a Board ... Medicine. The patented, revolutionary eDiscSculpt Technique created and used by Datta Endoscopic is ...
(Date:4/28/2017)... ... 2017 , ... People are starting to accept that hearing aids can be ... the stigma it had when great-grandpa wore his hearing aids years ago,” said Dr. ... North American Speaker Series (NASS) segment. “He probably wore an iPod-size hearing ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... assisting the Brooke Grove Foundation implement a Microsoft Dynamics GP solution that integrates ... leading ERP expert that specializes in long-term care, Brooke Grove now has the ...
(Date:4/28/2017)... ... April 28, 2017 , ... Christie Medical Holdings, Inc. , with ... B. Braun Medical Inc. , a leader in infusion therapy and pain management. ... many as 90 percent of hospital patients receiving a peripheral IV catheter as part ...
(Date:4/27/2017)... ... April 27, 2017 , ... The ... the 2017 Public Leadership in Neurology Award (PLINA). The couple joins a prestigious ... Bruschi, Vice President Walter Mondale, actor Michael J. Fox and former U.S. Attorney ...
Breaking Medicine News(10 mins):